Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) was the recipient of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 832,200 shares, a growth of 51.5% from the November 30th total of 549,400 shares. Approximately 3.8% of the shares of the stock are sold short. Based on an average daily volume of 78,700 shares, the short-interest ratio is presently 10.6 days.
Hedge Funds Weigh In On Gyre Therapeutics
A number of institutional investors have recently made changes to their positions in GYRE. FMR LLC purchased a new stake in Gyre Therapeutics during the 3rd quarter worth about $47,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Gyre Therapeutics by 392.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company's stock worth $1,425,000 after buying an additional 90,557 shares in the last quarter. Rhumbline Advisers purchased a new stake in shares of Gyre Therapeutics during the second quarter worth about $123,000. Renaissance Technologies LLC acquired a new position in shares of Gyre Therapeutics in the second quarter valued at approximately $166,000. Finally, WINTON GROUP Ltd purchased a new position in shares of Gyre Therapeutics during the second quarter valued at approximately $220,000. 23.99% of the stock is owned by institutional investors and hedge funds.
Gyre Therapeutics Price Performance
GYRE stock traded down $0.68 on Friday, reaching $12.45. The company had a trading volume of 155,388 shares, compared to its average volume of 75,608. The company's fifty day moving average is $12.71 and its 200 day moving average is $12.64. Gyre Therapeutics has a 1 year low of $8.26 and a 1 year high of $27.45.
Gyre Therapeutics Company Profile
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Featured Stories
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
